AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology ...

MoneyShow presents top investment ideas for 2026 from leading advisors. Part 1 includes AbbVie, Alexandria Real Estate ...

AbbVie has also pledged to participate in TrumpRx and offer many of its products, including Humira, on a direct-to-patient ...

AbbVie reached a deal with the Trump administration on drug prices in exchange for being exempted from tariffs and future ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

Hold iShares U.S. Healthcare ETF (IYH): top holdings face GLP-1 risks, patent cliffs and high valuations. Read here for an ...

Though far from the first large drugmaker to strike a pricing deal with the Trump administration, AbbVie’s new accord is ...

The Trump administration has finalized a deal with drugmaker AbbVie to cut the cost of certain medicines, marking the latest ...

AbbVie said on Monday that it has struck a three-year deal with U.S. President Donald Trump's administration to reduce drug prices, and has pledged $100 billion over the next decade for research and ...

Biopharmaceutical company AbbVie has reached an agreement with the Trump administration to invest $100 billion in its U.S.

Wednesday, January 14, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie ...

AbbVie commits to lowering Medicaid drug prices and investing $100 billion in US R&D and capital investments over the next decade. The TrumpRx program will expand direct-to-patient offerings, ...